BioTelemetry, Inc. (BEAT) Analysts See $0.31 EPS

July 14, 2018 - By Tamara Reed

BioTelemetry, Inc. (NASDAQ:BEAT) LogoInvestors sentiment increased to 1.38 in Q1 2018. Its up 0.50, from 0.88 in 2017Q4. It improved, as 21 investors sold BioTelemetry, Inc. shares while 53 reduced holdings. 34 funds opened positions while 68 raised stakes. 29.44 million shares or 6.24% more from 27.71 million shares in 2017Q4 were reported.
Northern holds 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 445,873 shares. Great West Life Assurance Can stated it has 39,525 shares. Regions Financial Corp holds 0% or 9,964 shares. Arizona State Retirement Systems reported 48,770 shares. 3,637 were accumulated by Riverhead Capital Limited Liability Co. State Street holds 0% or 833,647 shares in its portfolio. Thrivent For Lutherans invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Fifth Third National Bank holds 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 18,064 shares. Sterling Mgmt Ltd Liability holds 521,788 shares or 0.15% of its portfolio. Fiera Corp accumulated 137,043 shares. Ubs Asset Americas Inc owns 21,312 shares for 0% of their portfolio. The Iowa-based Dubuque Bankshares & Tru Com has invested 0.02% in BioTelemetry, Inc. (NASDAQ:BEAT). Arrowmark Colorado Lc owns 390,064 shares for 0.12% of their portfolio. Wisconsin-based Campbell Newman Asset Mgmt has invested 0.06% in BioTelemetry, Inc. (NASDAQ:BEAT). Credit Suisse Ag has invested 0.04% in BioTelemetry, Inc. (NASDAQ:BEAT).

Analysts expect BioTelemetry, Inc. (NASDAQ:BEAT) to report $0.31 EPS on August, 14.They anticipate $0.08 EPS change or 34.78 % from last quarter’s $0.23 EPS. BEAT’s profit would be $10.17M giving it 39.72 P/E if the $0.31 EPS is correct. After having $0.39 EPS previously, BioTelemetry, Inc.’s analysts see -20.51 % EPS growth. The stock increased 0.92% or $0.45 during the last trading session, reaching $49.25. About 330,680 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 47.53% since July 14, 2017 and is uptrending. It has outperformed by 34.96% the S&P500.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry has $5400 highest and $41.0 lowest target. $47.50’s average target is -3.55% below currents $49.25 stock price. BioTelemetry had 2 analyst reports since February 23, 2018 according to SRatingsIntel. The company was maintained on Friday, February 23 by Dougherty.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.62 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It currently has negative earnings. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

Another recent and important BioTelemetry, Inc. (NASDAQ:BEAT) news was published by Investorplace.com which published an article titled: “10 Small-Caps Leading the Market Rebound” on July 10, 2018.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.